Ultrastructural Immunostaining of Infiltrating Ductal Breast Carcinomas with the Monoclonal Antibody H: A Comparative Study with Cytokeratin 8

Ultrastructural Pathology

Volumn 27, Issue 6, 2003, Pages 393-407

  Havaki, Sophia ^a   Kittas, Christos ^a   Marinos, Evangelos ^a   Dafni, Urania ^b   Sotiropoulou, Christina ^b   Voloudakis Baltatzis, Irene ^c   Goutas, Nikos ^a   Vassilaros, Stamatis D ^d   Athanasiou, Evangelos ^e   Arvanitis, Dimitrios L ^e  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c SAINT SAVVAS HOSPITAL   (Greece)

^d Prolipsis Breast Diagnostic Center   (Greece)

^e UNIVERSITY OF THESSALY   (Greece)

Author keywords

Antibody H; Cytokeratin 8; Double immunogold labeling; Image analysis; Infiltrating ductal breast carcinoma; Ultrastructure

Indexed keywords

CYTOKERATIN 5; CYTOKERATIN 8; EPITOPE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY H; UNCLASSIFIED DRUG;

ANTIGEN RECOGNITION; ARTICLE; BREAST BIOPSY; BREAST CARCINOMA; BREAST FIBROADENOMA; CELL ULTRASTRUCTURE; COMPUTER ANALYSIS; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL;

MINK CELL FOCUS-FORMING VIRUS;

EID: 0346155817     PISSN: 01913123     EISSN: None     Source Type: Journal    
DOI: 10.1080/01913120390209875     Document Type: Article

References (87)

1. Henderson BE, Pike MC, Bernstein L, Ross RK. Breast cancer. In: Schottenfeld D, Fraumeni JF, eds. Cancer Epidemiology and Prevention, ed 2. Oxford, UK: Oxford University Press; 1996;1022-1039.
2. Rosen PP. The pathological classification of human mammary carcinoma: past, present and future. Ann Clin Lab Sci. 1979;9:144-156.
3. Tulinius H, Bjarnason O, Sigvaldason H, Bjarnadottir G, Olafsdottir G. Tumours in Iceland, 10; malignant tumours of the female breast - a histological classification, laterality, survival and epidemiological considerations. APMIS. 1988;96:229-238.
4. Rosen PP. Invasive duct carcinoma and morphological prognostic markers. In: Rosen PP, ed. Breast Pathology. Philadelphia: Lippincott-Raven; 1997;275-293.
5. Ahmed A. Atlas of the Ultrastructure of Human Breast Diseases. London: Churchill-Livingstone; 1978.
6. Gallager SH. Pathologic types of breast cancer: their prognoses. Cancer. 1984;53:623-629.
7. Goldenberg VE, Goldenberg NS, Sommers SC. Comparative ultrastructure of atypical ductal hyperplasia, intraductal carcinoma and infiltrating ductal carcinoma of the breast. Cancer. 1969;24:1152-1169.
8. Pucci-Minafra I, Minafra S, Faccini AM, Alessandro R. An ultrastructural evaluation of cell heterogeneity in invasive ductal carcinomas of the human breast, I: an in vivo study. J Submicrosc Cytol Pathol. 1989;21:475-488.
9. Querzoli P, Albonico G, Ferretti S, Rinaldi R, Magri E, Nenci I. Quantitative immunoprofiles of breast cancer performed by image analysis. Anal Quant Cytol Histol. 1999;21:151-160.
10. Altenstrasser F, Weger AR, Lindholm J, Gschwendter A, Mairinger T. Reproducibility and efficiency testing of two sampling methods for image analysis in cytology. Anal Quant Cytol Histol. 1998;20:92-96.
11. Ghadially FN. Diagnostic Electron Microscopy of Tumors, ed 2. London: Butterworths; 1985.
12. Djabali K. Cytoskeletal proteins connecting intermediate filaments to cytoplasmic and nuclear periphery. Histol Histopathol. 1999;14:501-509.
13. Dickersin GR. Diagnostic Electron Microscopy: A Text/Atlas, ed 2. New York: Springer; 2000.
14. Franke WW, Schiller DL, Moll R, et al. Diversity of cytokeratins: differentiation specific expression of cytokeratin polypeptides in epithelial cells and tissues. J Mol Biol. 1981;153:933-959.
15. Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalog of human cytokeratin polypeptides: patterns of expression of specific cytokeratins in normal epithelia, tumors and cultured cells. Cell. 1982;31:11-24.
16. Franke WW, Schiller DL, Hatzfeld M, Winter S. Protein complexes of intermediated-sized filaments: melting of cytokeratin complexes in urea reveals different polypeptide separation characteristics. Proc Natl Acad Sci USA. 1983;80:7113-7117.
17. Moll R, Schiller DL, Franke WW. Identification of protein IT of intestinal cytoskeleton as a novel type I cytokeratin with unusual properties and expression patterns. J Cell Biol. 1990;111:567-580.
18. Chu PG, Weiss LM. Keratin expression in human tissues and neoplasms. Histopathology. 2002;40:403-439.
19. Fuchs E, Coppock SM, Green H, Cleveland DW. Two distinct classes of keratin genes and their evolutionary significance. Cell. 1981:27:75-84.
20. Kim KH, Rheinwald JG, Fuchs E. Tissue specificity of epithelial keratins: differential expressions of mRNAs from two multigene families. Mol Cell Biol. 1983;3:495-502.
21. Kim KH, Marchuk D, Fuchs E. Expression of unusually large keratins during terminal differentiation: balance of type II keratins is not disrupted. J Cell Biol. 1984;99:1872-1877.
22. Fuchs E. Keratins as biochemical markers of epithelial differentiation. Trends Genet. 1988;4:277-281.
23. Franke WW, Schmid E, Weber K, Osborn M. HeLa cells contain intermediate-sized filaments of the prekeratin type. Exp Cell Res. 1979;118:95-109.
24. Van Muijen GNP, Ruiter DJ, Franke WW, et al. Cell type heterogeneity of cytokeratin expression in complex epithelia and carcinomas as demonstrated by monoclonal antibodies specific for cytokeratins 4 and 13. Exp Cell Res. 1986;162:97-113.
25. Osborn M, Weber K. Tumour diagnosis by intermediate filament typing: a novel tool for surgical pathology. Lab Invest. 1983;48:372-394.
26. Cooper DS, Schermer A, Sun TT. Classification of human epithelia and their neoplasms using monoclonal antibodies to keratins: strategies, applications and limitations. Lab Invest. 1985;52:243-256.
27. Gown AM, Vogel AM. Monoclonal antibodies to human intermediate filament proteins. Am J Clin Pathol. 1985;84:413-424.
28. Bartek J, Vojtesek B, Staskova Z, Bartkova J, Kerekes Z, Rejthar A. A series if 14 new monoclonal antibodies to keratins: characterization and value in diagnostic histopathology. J Pathol. 1991;164:215-224.
29. Miettinen M. Keratin immunohistochemistry: update on applications and pitfalls. Pathol Annu. 1993;8:113-143.
30. Jarasch ED, Nagle RB, Kaufmann M, Maurer C, Bocker WJ. Differential diagnosis of benign epithelial proliferations and carcinomas of the breast using antibodies to cytokeratins. Hum Pathol. 1988;19:276-289.
31. Trask DK, Band V, Zajchowski DA, Yaswen P, Suh T, Sager R. Keratins as markers that distinguish normal and tumor-derived mammary epithelial cells. Proc Natl Acad Sci USA. 1990;87:2319-2323.
32. Heatley M, Maxwell P, Whiteside C, Toner P. Cytokeratin intermediate filament expression in benign and malignant breast disease. J Clin Pathol. 1995;48:26-32.
33. Moll R, Krepler R, Franke WW. Complex cytokeratin polypeptide patterns observed in certain human carcinomas. Differentiation. 1983;23:256-269.
34. Quinlan RA, Schiller DL, Hatzfeld M, et al. Patterns of expression and organization of cytokeratin intermediate filaments. In: Wang E, Fishman D, Liem RRH, Sun T-T, eds. Intermediate Filaments. Ann NY Acad Sci. New York: NYAS 1985;455:282-306.
35. Takei H, Lino Y, Horiguchi J, et al. Immunohistochemical analysis of cytokeratin 8 as a prognostic factor in invasive breast carcinoma. Anticancer Res. 1995;15:1101-1106.
36. Godfroid E, Geuskens M, Dupressoir T, Parent I, Szpirer C. Cytokeratins are exposed on the outer surface of established human mammary carcinoma cells. J Cell Sci. 1991;99:595-607.
37. Hembrough TA, Vasudevan J, Allietta MM, Glass II WF, Gonias SL. A cytokeratin 8-like protein with plasminogen-binding activity is present on the external surfaces of hepatocytes, HepG2 cells and breast carcinoma cell lines. J Cell Sci. 1995;108:1071-1082.
38. Chan R, Rossitto PV, Edwards BF, Cardiff RD. Presence of proteolytically processed keratins in the culture medium of MCF-7 cells. Cancer Res. 1986;46:6353-6359.
39. Hembrough TA, Gonias SL. Cell-surface cytokeratin 8 is the major plasminogen receptor on breast cancer cells and is required for the accelerated activation of cell-associated plasminogen by tissue-type plasminogen activator. J Biol Chem. 1996;271:25684-25691.
40. Weber K, Osborn M, Moll R, Wiklund B, Luning B. Tissue polypeptide antigen (TPA) is related to the nonepidermal keratins 8, 18 and 19 typical of simple and nonsquamous epithelia: re-evaluation of a human tumor marker. EMBO J. 1984;3:2707-2714.
41. Arvanitis DL, Kouklis P, Mori de Moro G, Goutas N, Kittas C, Szuchet S. Immunostaining of ductal breast carcinoma with the monoclonal antibody H. Oncol Rep. 1995;2:991-995.
42. Arvanitis DL, Stavridou AI, Mori de Moro G, Szuchet S. Reactive astrocytes upregulate one or more gene products that are recognized by monoclonal antibody H. Cell Tissue Res. 2001;304:11-19.
43. Chou C-F, Smith AJ, Omary MB. Characterization and dynamics of O-linked glycosylation of human cytokeratins 8 and 18. J Biol Chem. 1992;267:3901-3906.
44. Haltiwanger RS, Kelly WG, Roquemore EP, et al. Glycosylation of nuclear and cytoplasmic proteins is ubiquitous and dynamic. Biochem Soc Trans. 1992;20:264-269.
45. Haltiwanger RS, Busby S, Grove K, et al. O-glycosylation of nuclear and cytoplasmic proteins: regulation analogous to phosphorylation? Biochem Biophys Res Commun. 1997;231:237-242.
46. Hart GW. Dynamic O-linked glycosylation of nuclear and cytoskeletal proteins. Annu Rev Biochem. 1997;66: 315-335.
47. Kreppel LK, Blomberg MA, Hart GW. Dynamic glycosylation of nuclear and cytosolic proteins. J Biol Chem. 1997;272:9308-9315.
48. Erlandson RA. Diagnostic Transmission Electron Microscopy of Tumors. New York: Raven Press, 1994.
49. Dvorak AM, Monahan-Earley RA. Diagnostic Ultrastructural Pathology, I. Boca Raton, CRC Press; 2000.
50. Tucker JA. The continuing value of electron microscopy in surgical pathology. Ultrastruct Pathol. 2000;24:383-389.
51. Ordóňez NG, Mackay B Electron microscopy in tumor diagnosis: indications for its use in the immunohistochemical era. Hum Pathol. 1998;29:1403-1411
52. Verkleij AJ, Koster AJ, Müller WH, Humberl BM. Immunogold labeling in transmission electron microscopy. In: Thiery JP, ed. Molecular Mechanisms of Transcellular Signaling. Amsterdam: IOS Press; 1999:339-355.
53. Faulk WP, Taylor GM. An immunocolloid method for the electron microscope. Immunocytochemistry. 1971;8:1081-1083.
54. Beier K, Fahimi HD. Automatic determination of labeling density in protein A-gold immunocytochemical preparations using an image analyzer: application to peroxisomal enzymes. Histochemistry. 1985;82:99-100.
55. Pulczynski S, Jensen OM. Quantitation of immunogold with an interactive image analysis system: a new, practical approach to antibody-induced modulation, internalization and intracellular transport of surface antigens in viable hematopoietic cells. Anal Quant Cytol Histol. 1994;16:393-399.
56. Gracia-Navarro F, Ruiz-Navarro A, Garcia-Navarro S, Castaňo J. Transmission electron microscopy. In: Wootton R, Springall DR, Polak JM, eds. Image Analysis in Histology: Conventional and Confocal Microscopy. Cambridge, UK: Cambridge University Press; 1995:197-210.
57. Hisano S, Adachi T, Maegawa M, Daikoku S. Some improvement in tissue preparation and colloidal-gold immunolabeling for electron microscopy. Am J Anat. 1986;175:245-266.
58. Slot JW, Posthuma G, Ghang LY, Crapo JD, Geuze HJ. Quantitative aspects of immunogold labeling in embedded and in nonembedded sections. Am J Anat. 1989;185:271-281.
59. Fahimi HD, Reich D, Volkl A, Baumgart E. Contributions of the immunogold technique to investigation of the biology of peroxisomes. Histochem Cell Biol. 1996;106:105-114.
60. Bloom HJG, Richardson HH. Histological grading and prognosis in breast cancer: a study of 1409 cases of which 359 have been followed for fifteen years. Br J Cancer. 1957;11:359-377.
61. Causton B. The choice of resins for electron immunocytochemistry. In: Polak JM, Varndell IM, eds. Immunolabelling for Electron Microscopy. Amsterdam: Elsevier; 1984:29-36.
62. Bendayan M, Zollinger M. Ultrastructural localization of antigenic sites on osmium-fixed tissues applying the protein A-gold technique. J Histochem Cytochem. 1983;31:101-109.
63. Polak JM, Van Noorden S. Post-embedding immunocytochemistry for the transmission electron microscope. In: Polak JM, Van Noorden S, eds. Introduction to Immunocytochemistry. Oxford, UK: Bios Scientific; 1997:81-89.
64. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics. 1982;38:963-974.
65. Holt GD, Hart GW. The subcellular distribution of terminal N-acetylglucosamine moieties: localization of a novel protein-saccharide linkage, O-linked GlcNAc. J Biol Chem. 1986;261:8049-8057.
66. Chandra NC, Spiro MJ, Spiro RG. Identification of a glycoprotein from rat liver mitochondrial inner membrane and demonstration of its origin in the endoplasmic reticulum. J Biol Chem. 1998;273:19715-19721.
67. Görlach M, Meyer HE, Elsermann B, Soboll S. cAMP-dependent phosphorylation of cytokeratin in hepatic inner mitochondrial membrane. Biol Chem Hoppe-Seyler. 1995;376:51-55.
68. Abeijon C, Hirschberg CB. Intrinsic membrane glycoproteins with cytosol-oriented sugars in the endoplasmic reticulum. Proc Natl Acad Sci USA. 1988;85:1010-1014.
69. Kelly WG, Hart GW. Glycosylation of chromosomal proteins: localization of O-linked N-acetylglucosamine in Drosophila chromatin. Cell. 1989;57:243-251.
70. Jackson SP, Tjian R. Purification and analysis of RNA polymerase II transcription factors by using wheat germ agglutinin affinity chromatography. Proc Natl Acad Sci USA. 1989;86:1781-1785.
71. Reason AJ, Morris HR, Panico M, et al. Localization of O-GlcNAc modification on the serum response transcription factor. J Biol Chem. 1992;267:16911-16921.
72. Privalsky ML. A subpopulation of the avian erythroblastosis virus v-erbA protein, a member of the nuclear hormone receptor family, is glycosylated. J Virol. 1990;64:463-466.
73. Chou T-Y, Hart GW, Dang CV. c-Myc is glycosylated at threonine 58, a known phosphorylation site and a mutational hot spot in lymphomas. J Biol Chem. 1995;270:18961-18965.
74. Shaw P, Freeman J, Bovey R, Iggo R. Regulation of specific DNA binding by p53: evidence for a role for O-glycosylation and charged residues at the carboxy-terminus. Oncogene. 1996;12:921-930.
75. Jiang MS, Hart GW. A subpopulation of estrogen receptors are modified by O-linked N-acetylglucosamine. J Biol Chem. 1997;272:2421-2428.
76. Cheng X, Hart GW. Glycosylation of the murine estrogen receptor-alpha. J Steroid Biochem Mol Biol. 2000;75:147-158.
77. Ward WS, Schmidt WN, Schmidt CA, Hnilica LS. Association of cytokeratin p39 with DNA in intact Novikoff hepatoma cells. Proc Natl Acad Sci USA. 1984;81:419-423.
78. Tolstonog GV, Sabasch M, Traub P. Cytoplasmic intermediate filaments are stably associated with nuclear matrices and potentially modulate their DNA-binding function. DNA Cell Biol. 2002;21:213-239.
79. Spencer VA, Coutts AS, Samuel SK, Murphy LC, Davie JR. Estrogen regulates the association of intermediate filament proteins with nuclear DNA in human breast cancer cells. J Biol Chem. 1998;273:29093-29097.
80. Dolo V, Adobati E, Canevari S, Picone MA, Vittorelli ML. Membrane vesicles shed into the extracellular medium by human breast carcinoma cells carry tumor-associated surface antigens. Clin Exp Metastasis. 1995;13:277-286.
81. Leube RE, Bosch FX, Romano V, Zimbelmann R, Hofler H, Franke WW. Cytokeratin expression in simple epithelia, III: detection of mRNAs encoding human cytokeratins nos. 8 and 18 in normal and tumor cells by hybridization with cDNA sequences in vitro and in situ. Differentiation. 1986;33:69-85.
82. Sundstrom BE, Stigbrand TI. Cytokeratins and tissue polypeptide antigen. Int J Biol Markers. 1994;9:102-108.
83. Gonias SL, Hembrough TA, Sankovic M. Cytokeratin 8 functions as a major plasminogen receptor in select epithelial and carcinoma cells. Front Biosci. 2001;6:1403-1411.
84. Riopel CL, Butt I, Omary MB. Method of cell handling affects leakiness of cell surface labeling and detection of intracellular keratins. Cell Motil Cytoskel. 1993;26:77-87.
85. Asch HL, Mayhew E, Lazo RO, Asch BB. Lipids covalently bound to keratins of mouse mammary epithelial cells. Biochem Mol Biol Int. 1993;29:1161-1169.
86. Slawson C, Pidala J, Potter R. Increased N-acetyl-β-glucosaminidase activity in primary breast carcinomas corresponds to a decrease in N-acetylglucosamine containing proteins. Biochim Biophys Acta. 2001;1537:147-157.
87. Zachara NE, Hart GW. The emerging significance of O-GlcNAc in cellular regulation. Chem Rev. 2002;102:431-438.